Editas Medicine
EDIT
237 hedge funds and large institutions have $517M invested in Editas Medicine in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 39 closing their positions.
73% more call options, than puts
Call options by funds: $8.36M | Put options by funds: $4.83M
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
35% more capital invested
Capital invested by funds: $384M → $517M (+$133M)
10% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 39
1% more funds holding
Funds holding: 234 → 237 (+3)
1.04% more ownership
Funds ownership: 76% → 77.04% (+1%)
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$30.1M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$26.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$24.7M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$8.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.39M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.22M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.48M |
| 5 |
Citigroup
New York
|
-$3.88M |
EDIT Hedge Fund Activity: Q2 2023 in Review
237 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2023, worth a combined $517M — up 35% from $384M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new EDIT positions and 39 closed out — a net gain of 4 holders — while 75 added to existing stakes and 48 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $30.1M. The largest seller was State Street, cutting an estimated $13.3M.
- 237 institutional investors held Editas Medicine (EDIT) as of Q2 2023, up from 234 in Q1 2023.
- Funds reported $517M of Editas Medicine stock for Q2 2023, up 35% quarter-over-quarter.
- 43 funds opened new Editas Medicine positions in Q2 2023 and 39 closed out, a net change of +4 holders.
- The largest Editas Medicine buyer in Q2 2023 was Deep Track Capital, an estimated $30.1M added.
- The largest Editas Medicine seller in Q2 2023 was State Street, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2023.